Welcome to our dedicated page for Qualigen Therapeutics SEC filings (Ticker: QLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Qualigen Therapeutics, Inc. (historically NASDAQ: QLGN and now AIxCrypto Holdings, Inc. with symbol AIXC) provide detailed insight into the company’s transformation from a clinical-stage biotechnology issuer into a business that also emphasizes crypto, Web3, and decentralized AI activities. Through current reports on Form 8-K, registration statements on Form S-1, and proxy materials, investors can track how the company structures its financings, governs its operations, and discloses risks.
In its Form S-1 registration statement, the company outlines its current business mix: one early-clinical-stage program (QN-302), one preclinical Pan-RAS therapeutic program, and the C10 Cryptocurrency Asset Treasury with an 80% passive and 20% active allocation strategy to top cryptocurrencies. The S-1 also describes the terms of the Series B Convertible Preferred Stock, including conversion mechanics, voting rights, and the number of common shares that may be issued upon conversion, as well as the resale registration for those shares.
Multiple Form 8-K filings document the $41 million PIPE financing led by Faraday Future Intelligent Electric Inc., the Subscription Agreement and Registration Rights Agreement, and the Lead Investor Agreement that grants Faraday Future board nomination rights and participation rights in future financings. These filings also cover significant changes in senior management and the board of directors, the appointment and resignation of auditors, and Nasdaq correspondence regarding shareholder approval under Listing Rule 5635(b) and equity compliance under Listing Rule 5550(b)(1).
Additional filings, including the DEF 14A proxy statement, present the proposals submitted to stockholders, such as approval of the PIPE-related issuances and the 2025 Equity Incentive Plan. Name and ticker changes from Qualigen Therapeutics, Inc. (QLGN) to AIxCrypto Holdings, Inc. (AIXC) are recorded through amendments to the certificate of incorporation and related 8-K disclosures.
On Stock Titan’s filings page, users can review these documents as they are made available through EDGAR and use AI-powered summaries to understand complex items like preferred stock designations, treasury policies, and Nasdaq compliance matters. The page also surfaces key forms such as 10-Q and 10-K when filed, along with any future Form 4 insider transaction reports, to help readers analyze capital structure, governance developments, and the evolution of the company’s dual focus on therapeutics and AI × Web3 initiatives.
Qualigen Therapeutics, Inc. (QLGN) reported a challenging quarter with limited cash and ongoing operating losses. The company had approximately $332,000 in cash and an accumulated deficit of $127.4 million. For the six months ended June 30, 2025 the company used $2.7 million in operating cash and $6.3 million for the year ended December 31, 2024. Loss from continuing operations was $4.33 million for the period versus $3.51 million in the prior comparative period. Short-term borrowings included $3.64 million from nine investors and additional promissory notes totaling $2.3 million. Subsequent to period end, the company closed a private placement in July 2025 raising net proceeds of $4.258 million, which management expects will provide liquidity through year-end. The filing discloses multiple convertible debentures, warrant re-pricings, preferred stock conversions, a 2024 reverse stock split, and a $468,000 loan loss reserve related to Marizyme notes.
Qualigen Therapeutics, Inc. filed a Form D reporting a completed Regulation D offering that raised $4,500,000 in equity securities. The offering consisted of convertible preferred stock that can convert into common shares and was conducted under Rule 506(b). The issuer reports 14 investors and indicates the total offering amount sold equals the offering amount, with $0 remaining to be sold. The company listed no sales commissions or finders' fees (estimated) and stated $0 of gross proceeds will be used for payments to named executive officers or directors (estimate). The issuer declined to disclose revenue/net asset size. The offering was not part of a business combination and the issuer named Univest Securities LLC as the associated broker-dealer.
Alpha Capital Anstalt has filed Amendment No. 2 to Schedule 13G for Qualigen Therapeutics (QLGN).
- Beneficial ownership: 36,434 common shares.
- Ownership percentage: 2.223 % of the 1,635,475 shares outstanding as of 18 Jul 2025.
- Voting & dispositive power: Sole power over all reported shares; no shared power.
- Filer details: Liechtenstein entity, address Altenbach 8, FL-9490 Vaduz.
- Purpose: Certified as a passive investment with no intent to influence control.
The update simply records Alpha Capital’s sub-5 % stake; it carries limited strategic or valuation implications for QLGN shareholders.
On 23 Jul 2025 Qualigen Therapeutics (Nasdaq:QLGN) received a Nasdaq notice that its stockholders’ equity, as reported in the 31 Mar 2025 Form 10-Q, fell below the $2.5 million minimum required by Listing Rule 5550(b)(1). On 24 Jul 2025 Nasdaq’s Office of the General Counsel granted an extension after reviewing the company’s compliance plan and a pro-forma balance sheet reflecting a $4.5 million private placement of Series A-3 preferred stock, which would raise equity above the threshold.
Nasdaq accepted the plan, giving the company up to 12 months to evidence sustained compliance. Management is working to maintain the Nasdaq Capital Market listing but offers no assurance of success. Supporting materials include a press release dated 28 Jul 2025 (Ex. 99.1) and an unaudited pro-forma balance sheet (Ex. 99.2).
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) filed a Form 8-K announcing a board-level governance change effective June 20 2025. Independent director Robert B. Lim was appointed Chair of the Audit Committee, succeeding Graydon Bensler, who will remain a committee member. The board affirmed that Lim meets Nasdaq Rule 5605 and SEC Rule 10A-3 independence criteria and is deemed an “audit committee financial expert” under Regulation S-K Item 407(d)(5). The filing states there are no related-party transactions or special arrangements connected to Lim’s elevation. No other management changes, financial results, or transactions were disclosed.